Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study

Li-Yang Hu1,2,3†, Xiao-Lu Xu1,2†, Hui-Lan Rao1,4, Jie Chen5,6, Ren-Chun Lai1,7, Hui-Qiang Huang1,2, Wen-Qi Jiang1,2, Tong-Yu Lin1,2, Zhong-Jun Xia1,8 and Qing-Qing Cai1,2*

Abstract

Background: The programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway inhibits the activation of T cells and plays a crucial role in the negative regulation of cellular and humoral immune responses. Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults. In the present study, we aimed to detect the expression of PD-L1 in DLBCL and to analyze its relationship with prognosis.

Methods: We reviewed medical records of 204 newly diagnosed DLBCL patients in Sun Yat-sen University Cancer Center between October 2005 and August 2012. The expression of PD-L1 in tumor tissues from these 204 patients was detected using immunohistochemical (IHC) assay. The expression of anaplastic lymphoma kinase (ALK), CD5, CD30, and C-Myc in tumor specimens from 109 patients was detected using IHC, and Epstein–Barr virus (EBV)-encoded RNAs (EBERs) were detected using fluorescence in situ hybridization. The Spearman method was used for correlation analysis. The Kaplan–Meier method with log-rank test was used for univariate analysis. Cox proportional hazards model was used for multivariate analysis.

Results: Of the 204 patients, 100 (49.0%) were PD-L1-positive in tumor cells and 44 (21.6%) were PD-L1-positive in tumor microenvironment. PD-L1 expression in tumor cells and tumor microenvironment were more common in the non-germinat center B-cell-like (GCB) subtype than in the GCB subtype ($P = 0.02$ and $P = 0.04$). Patients with PD-L1 expression in tumor microenvironment were more likely to be resistant to first-line chemotherapy when compared with the patients without PD-L1 expression in tumor microenvironment ($P = 0.03$). PD-L1 expression in tumor microenvironment was negatively correlated with C-Myc expression ($r = -0.20$, $P = 0.04$). No correlations were detected between PD-L1 expression and the expression of ALK, CD5, and CD30 as well as EBERs. The 5-year overall survival (OS) rates were 50.0% and 67.3% in patients with and without PD-L1 expression in tumor cells ($P = 0.02$). PD-L1 expression in tumor cells was an independent risk predictor for OS ($P < 0.01$).

Conclusions: PD-L1 expression is more common in the non-GCB subtype than in the GCB subtype. PD-L1 expression in tumor microenvironment has a negative correlation with C-Myc. PD-L1 positivity predicts short survival in DLBCL patients. For patients with PD-L1 expression, more strategy such as anti-PD-L1 antibody treatment should be recommended.

© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Programmed cell death-ligand 1 (PD-L1), a member of the B7 family (also known as B7-H1), is an inhibitory ligand expressed on the surface of macrophages, dendritic cells, fibroblasts, and T cells [1, 2]. Binding of PD-L1 to its receptor, programmed cell death 1 (PD-1), inhibits cytokine production and cell cycle progression of T cells [3–5]. It functions as an important checkpoint in the regulation of cellular and humoral immune responses [6]. Adaptive immune responses that include PD-1/PD-L1 expression are associated with cancer relapse [7]. PD-1/PD-L1 is an important axis that has important roles in the infiltration of various immune effectors and in the propensity to develop metastatic disease. Recent evidence suggests that activation of the PD-1/PD-L1 pathway represents one mechanism that allows tumors to elude the host immune system [8]. Previous studies have reported that PD-L1 is involved in the negative regulation of immune responses by binding to the PD-1 receptor and results in cancer cells evading the host immune surveillance and the promotion of metastasis [9].

Aberrant PD-L1 expression was reported in a number of human malignancies [1, 7, 10]. Evidence suggests that PD-L1 expression is associated with prognosis of certain types of cancers [11–16]. The PD-1/PD-L1 axis has attracted wide attention in the treatment of cancers such as lymphoma [17–19]. It has been proposed that immunotherapy can be combined with targeted therapy [4, 6]. Therapeutic PD-1/PD-L1 checkpoint inhibitors target the PD-1/PD-L1 immune checkpoint to restore the cancer cell-directed immune response [2, 20, 21]. Monoclonal antibodies directed against the PD-1/PD-L1 axis have shown clinical activity in several solid tumors including ovarian cancer [21], melanoma [22], renal cell carcinoma [23, 24], lung cancer [25], and colorectal cancer [26]. The use of a signaling inhibitor to reduce PD-L1 expression together with anti-PD-1 antibodies showed a promising durable effect against malignant diseases [27, 28].

As a group of heterogeneous diseases, diffuse large B-cell lymphoma (DLBCL) can be divided into different clinical and pathological subtypes as well as molecular and immunophenotypic subgroups [29, 30]. Anaplastic lymphoma kinase (ALK) [31], CD5 [32], CD30 [33], C-Myc [34], and Epstein–Barr virus (EBV)-encoded RNAs (EBERs) [35] are all important markers expressed in DLBCL that may predict prognosis. PD-L1 is also expressed on DLBCL tumor cells and tumor-infiltrating non-malignant cells, primarily macrophages [36]. Macrophages constitute a major source of PD-L1 expression in the tumor microenvironment of lymphomas. Interactions between tumor cells and the immune system are critical in defining disease biology in B-cell lymphomas [37, 38].

It is suggested that coordinate regulation of PD-L1 among tumor cells and tumor-infiltrating macrophages may exist [36]. Research revealed that in B-cell malignancies, the tumor microenvironment releases survival and proliferation signals and contributes to disease progression, drug resistance, and disease relapse [39]. The PD-1/PD-L1 signaling axis plays a critical role in patients with a large amount of tumor-infiltrating macrophages and is related with an inferior clinical outcome through the suppression of anti-tumor immunity [36].

Several studies have reported the expression of PD-L1 in lymphoma and described its relationship with prognosis [5, 40, 41]. However, similar studies on PD-L1 expression in DLBCL in China are rare. The clinicopathological characteristics of PD-L1-positive DLBCL patients are still controversial. In the present study, we retrospectively assessed the expression of PD-L1 in DLBCL tissues and analyzed its association with clinicopathological features and prognosis of patients with DLBCL.

Patients and methods
Patient selection
Clinical data were collected from the database of the Department of Medical Oncology, Sun Yat-sen University Cancer Center (Guangzhou, China).

The inclusion criteria were as follows: (1) patients with newly diagnosed DLBCL treated at the Sun Yat-sen University Cancer Center between October 2005 and August 2012; (2) patients were diagnosed using biopsy according to the 2001 or 2008 World Health Organization classification; (3) patients were 18 years of age or older; (4) patients had received first-line chemotherapy regimens, such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or R-CHOP-like regimen, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or CHOP-like regimen, and MA regimen (high-dose methotrexate and cytarabine) with curative intent; (5) patients were not infected with human immunodeficiency virus and were not with immunodeficiency disease or second tumor; and (6) complete clinical information was available, including follow-up data. The Ann Arbor staging system and the international prognostic index (IPI) were used for staging evaluation and risk stratification respectively.
Follow-up
After treatment, patients were followed up every 3 months in the first 3 years and every 6 months thereafter. The final date of follow-up was March 31st, 2016. Routine examinations including physical examination, standard laboratory tests, echocardiography, and a whole-body computed tomography (CT) scan or fluorodeoxyglucose positron emission tomography (FDG-PET) were performed during follow-up. Overall survival (OS) was defined as the duration from pathological diagnosis to death or the last follow-up. Progression-free survival (PFS) was defined as the duration from pathological diagnosis to death, disease progression, or the last follow-up. Patients without any event at the last visit were censored.

Statistical analysis
Chi square test or Fisher’s exact test was used to analyze the relationship between PD-L1 expression in tumor cells/tumor microenvironment and clinicopathological characteristics of DLBCL patients. Pearson’s test was used to analyze the correlation between indexes. The Kaplan–Meier method was used to establish survival curves, and log-rank test was used for univariate analyses. The Cox proportional hazards model was used for multivariate analysis. All statistical analyses used 0.05 as the significance level (two-sided test) and were performed by using SPSS version 19.0 (IBM, Armonk, NY, USA).

Results
Patient characteristics
Clinical data of 204 patients with DLBCL were included in our analysis. The detailed baseline characteristics according to PD-L1 expression in tumor cells and tumor microenvironment are shown in Table 1. Among these patients, 115 (56.4%) were male, and 89 (43.6%) were female. The median age was 52 years (range 18–86 years). One hundred and one (49.5%) patients received R-CHOP/R-CHOP-like regimen as first-line treatment, 97 (47.5%) patients received CHOP/CHOP-like regimen, and 6 (2.9%) patients with central nervous system involvement received high-dose methotrexate and cytarabine. The median number of chemotherapy cycles was 6 (range 1–9). Overall, 104 (51.0%) patients had advanced stage (stages III and IV) disease; 61 (29.9%) had GCB subtype, and 138 (67.6%) had non-GCB-subtype disease. There were 100 (49.0%) patients with PD-L1 expression in tumor cells and 44 (21.6%) with PD-L1 expression in tumor microenvironment. With a median follow-up of 52 months (range 1–114 months), 98 (48.0%) patients experienced disease progression or died.

The expression statuses of ALK, CD5, CD30, C-Myc, and EBERs were only detected in samples from 109 patients because of the insufficient amount of pathological specimens. ALK was only detected in 1 (0.9%) patient; CD5 was positive in 9 (8.3%) patients; CD30 was positive in 16 (14.7%) patients; C-Myc was positive in 18 (16.5%) patients; C-Myc and BCL2 co-expression was observed in 17 (15.6%) patients; and C-Myc and BCL6 co-expression was observed in 9 (8.3%) patients; 9 (8.3%) patients were EBER-negative.
Table 1  Clinicopathological characteristics of 204 patients with diffuse large B-cell lymphoma (DLBCL) according to the expression of programmed cell death-ligand 1 (PD-L1) in tumor cells and tumor microenvironment

| Characteristic                  | PD-L1 expression in tumor cells [cases (%)] | P value | PD-L1 expression in tumor microenvironment [cases (%)] | P value |
|--------------------------------|--------------------------------------------|---------|--------------------------------------------------------|---------|
|                                | Negative | Positive |                           | Negative | Positive |
| Total                          | 104      | 100      |                           | 160      | 44       |
| Gender                         |          |          |                           |          |          |
| Male                           | 63 (60.6) | 52 (52.0) | 0.22                     | 93 (58.1) | 22 (50.0) | 0.34 |
| Female                         | 41 (39.4) | 48 (48.0) |                           | 67 (41.9) | 22 (50.0) |
| Age (years)                    |          |          |                           |          |          |
| ≤ 60                           | 73 (70.2) | 72 (72.0) | 0.78                     | 114 (71.2) | 31 (70.5) | 0.92 |
| > 60                           | 31 (29.8) | 28 (28.0) |                           | 46 (28.8) | 13 (29.5) |
| Clinical stage                 |          |          |                           |          |          |
| I–II                           | 58 (55.8) | 42 (42.0) | 0.04                     | 83 (51.9) | 17 (38.6) | 0.12 |
| III–IV                         | 46 (44.2) | 58 (58.0) |                           | 77 (48.1) | 27 (61.4) |
| B symptoms                     |          |          |                           |          |          |
| No                             | 75 (72.1) | 70 (70.0) | 0.74                     | 117 (73.1) | 28 (63.6) | 0.22 |
| Yes                            | 29 (27.9) | 30 (30.0) |                           | 43 (26.9) | 16 (36.4) |
| Spleen involvement             |          |          |                           |          |          |
| No                             | 92 (88.5) | 82 (82.0) | 0.19                     | 139 (86.9) | 35 (79.5) | 0.22 |
| Yes                            | 12 (11.5) | 18 (18.0) |                           | 21 (13.1) | 9 (20.5) |
| IPI                            |          |          |                           |          |          |
| < 3                            | 86 (82.7) | 73 (73.0) | 0.09                     | 128 (80.0) | 31 (70.5) | 0.18 |
| ≥ 3                            | 18 (17.3) | 27 (27.0) |                           | 32 (20.0) | 13 (29.5) |
| Extranodal involvement         |          |          |                           |          |          |
| No                             | 42 (40.4) | 44 (44.0) | 0.67                     | 67 (41.9) | 19 (43.2) | 0.88 |
| Yes                            | 62 (59.6) | 56 (56.0) |                           | 93 (58.1) | 25 (56.8) |
| Bulky diseasea                 |          |          |                           |          |          |
| No                             | 56 (70.0) | 63 (69.2) | 0.91                     | 92 (69.2) | 27 (71.1) | 0.82 |
| Yes                            | 24 (30.0) | 28 (30.8) |                           | 41 (30.8) | 11 (28.9) |
| LDHb (U/L)                     |          |          |                           |          |          |
| ≤ 245                          | 55 (55.6) | 44 (47.3) | 0.25                     | 81 (53.6) | 18 (43.9) | 0.27 |
| > 245                          | 44 (44.4) | 49 (52.7) |                           | 70 (46.4) | 23 (56.1) |
| ALPb (U/L)                     |          |          |                           |          |          |
| ≤ 110                          | 93 (92.1) | 86 (86.0) | 0.17                     | 138 (87.9) | 41 (93.2) | 0.42 |
| > 110                          | 8 (7.9) | 14 (14.0) |                           | 19 (12.1) | 3 (6.8) |
| β2-MGc (mg/L)                  |          |          |                           |          |          |
| ≤ 2.52                         | 25 (69.4) | 21 (48.8) | 0.06                     | 41 (66.1) | 5 (29.4) |
| > 2.52                         | 11 (30.6) | 22 (51.2) |                           | 21 (33.9) | 12 (70.6) |
| Ki-67 (%)                      |          |          |                           |          |          |
| < 90                           | 45 (61.6) | 45 (64.3) | 0.74                     | 70 (63.6) | 20 (60.6) | 0.75 |
| ≥ 90                           | 28 (38.4) | 25 (35.7) |                           | 40 (36.4) | 13 (39.4) |
| GCB subtypef                   |          |          |                           |          |          |
| Non-GCB                        | 61 (61.6) | 77 (77.0) | 0.02                     | 102 (65.8) | 36 (81.8) | 0.04 |
| GCB                            | 38 (38.4) | 23 (23.0) |                           | 53 (34.2) | 8 (18.2) |
| Rituximabg                     |          |          |                           |          |          |
| No                             | 40 (43.0) | 42 (46.7) | 0.62                     | 59 (41.5) | 23 (56.1) | 0.10 |
| Yes                            | 53 (57.0) | 48 (53.3) |                           | 83 (58.5) | 18 (43.9) |
| First-line chemotherapy CRh    |          |          |                           |          |          |
| No                             | 31 (33.7) | 31 (36.9) | 0.61                     | 46 (32.6) | 16 (45.7) | 0.15 |
| Yes                            | 61 (66.3) | 53 (63.1) |                           | 95 (67.4) | 19 (54.3) |
Relationship of PD-L1 with clinicopathologic characteristics

PD-L1 expression in tumor cells was associated with the non-GCB subtype (P = 0.02). PD-L1 expression in tumor microenvironment was associated with the non-GCB subtype (P = 0.04), elevated β2-MG level (P = 0.01), and resistance to first-line chemotherapy (P = 0.03). The expression level of PD-L1 in tumor microenvironment had a negative correlation with that of C-Myc (r = -0.20, P = 0.04). No correlation of the expression level of PD-L1 in tumor cells with that of C-Myc was observed. There was no significant association of PD-L1 expression in either tumor cells or microenvironment with CD5, CD30, C-Myc, and EBERs.

Survival analysis

The 5-year OS rate was 59.5%, and the 5-year PFS rate was 50.0% for the 204 DLBCL patients. Patients with PD-L1 expression in tumor cells had significantly lower 5-year OS rate (50.0% vs. 67.3%, P = 0.02) and 5-year PFS rate (39.6% vs. 59.6%, P = 0.01) than did patients without PD-L1 expression in tumor cells; the 5-year OS and PFS rates were similar between patients with and without PD-L1 expression in tumor microenvironment (Fig. 1).

Univariate analysis showed that age of older than 60, stage III–IV disease, with B symptoms, with spleen involvement, IPI no less than 3, serum lactate dehydrogenase (LDH) level higher than 245 U/L, failure to achieve complete remission (CR) after first-line chemotherapy, and PD-L1 expression in tumor cells were significantly associated with short OS and PFS; β2-MG level higher than 2.52 mg/L and lack of rituximab treatment were only significantly associated with short OS (Table 2). Factors that were significant in univariate analysis were included in the multivariate analysis.

In multivariate analyses, age [hazard ratio (HR) 1.38; 95% confidence interval (CI) 1.69–9.40; P < 0.01], CR after first-line chemotherapy (HR = 1.54; 95% CI 0.09–0.49; P < 0.01), and PD-L1 expression in tumor cells (HR 1.40; 95% CI 1.23–3.23; P = 0.01) was an independent predictor for PFS (Table 3).

Discussion

In the present study, we investigated the expression of PD-L1 in tumor cells and in tumor microenvironment in DLBCL patients. PD-L1 expression in tumor cells was significantly associated with poor prognosis. We also found that PD-L1 expression in tumor microenvironment was associated with resistance to first-line chemotherapy and the expression level of PD-L1 in tumor microenvironment was negatively correlated with that of C-Myc. Furthermore, the non-GCB subtype was
associated with PD-L1 expression in either tumor cells or tumor microenvironment.

PD-L1 expression in B-cell lymphomas is uncommon [15]. Generally, low-grade B-cell lymphoproliferative disorders are thought to rarely express PD-L1 [14]. Nevertheless, it was also reported that follicular lymphoma and DLBCL involved several immune escape pathways, suggesting that escape from antitumor immunity was essential in these aggressive lymphomas [42]. Efforts have been made to identify biomarkers of a response to immune checkpoint blockade, in order to identify the subsets of patients who are most likely to benefit from immune checkpoint blockade treatment. Currently, no biomarkers are generally recognized. In the present study, PD-L1 was found to be an independent predictor for OS and the non-GCB subtype was associated with PD-L1 expression in either tumor cells or tumor microenvironment. Besides, PD-L1 expression in tumor cells were associated with high β2-MG and advanced stage, demonstrating its role as an adverse prognostic factor in DLBCL. In another study, PD-L1 expression level was positively correlated with the number of PD-1-positive T cells in activated B-cell-like (ABC)-subtype DLBCL specimens, but was negatively correlated with the number of forkhead box P3 (FOXP3)-positive regulatory T cells in GCB-subtype DLBCL specimens [5]. On the basis of these findings, it may confer that immune evasion owing to PD-L1 expression in tumor cells might be associated with the poor clinical outcomes of patients with ABC-subtype DLBCL. Conversely, the lack of PD-L1 expression in GCB-subtype DLBCL specimens is a plausible explanation for the favorable prognosis associated with this disease subtype [43]. Therefore, PD-L1 expression in tumor cells may be a potential candidate biomarker of response to inhibitors of the PD-1/PD-L1 axis. Immunotherapy targeting the PD-1/PD-L1 pathway may benefit patients with DLBCL, particularly those with non-GCB-subtype DLBCL, which might benefit from blockade of the PD-1/PD-L1 immune checkpoint.

We set the threshold of at least 5% of lymphoma cells with PD-L1 expression for PD-L1 positivity in tumor

Fig. 1 Kaplan-Meier overall survival (OS) and progression-free survival (PFS) curves of patients with diffuse large B-cell lymphoma (DLBCL) according to the expression of programmed cell death-ligand 1 (PD-L1) in tumor cells and microenvironment. a, b Patients with PD-L1 expression in tumor cells had significantly lower 5-year OS rate ($P = 0.02$) and 5-year PFS rate ($P < 0.01$) compared with patients without PD-L1 expression in tumor cells. c, d The 5-year OS rate ($P = 0.21$) and 5-year PFS rate ($P = 0.26$) were similar between patients with and without PD-L1 expression in tumor microenvironment.
cells and at least 20% of malignant and non-malignant cells with PD-L1 expression for PD-L1 positivity in tumor microenvironment, conforming to the cut-point used in a previous publication [14]. We observed that 49.0% of patients were PD-L1-positive in tumor cells and 21.6% were PD-L1-positive in tumor microenvironment, which were comparable with those observed in a previous study [42]. Several researchers analyzed the expression of PD-L1 in tumor cells and tumor microenvironment in DLBCL using other standards. Kiyasu et al. [5] defined PD-L1 positivity in tumor cells as over 30% of lymphoma cells staining of both PD-L1 and paired box gene 5 (PAX5); when PD-L1-positive non-malignant stromal cells constituted over 20% of the total tissue from patients without PD-L1 expression in tumor cells, the sample was considered PD-L1-positive in tumor microenvironment. In their study, PD-L1 positivity in tumor cells and tumor microenvironment were observed in 10.5% and 15.3% of DLBCL patients. The higher rates of PD-L1 expression in tumor cells and tumor microenvironment in our cohorts may due to the race and different experimental standards. Fang et al. [43] detected the expression of PD-L1 in tumor tissues from 76 Chinese DLBCL patients and found that PD-L1 was expressed in tumor cells in 26.3% of patients. The smaller sample size in their study may explain the discrepancy.

### Table 2 Univariate analysis of prognostic factors for overall survival (OS) and progression-free survival (PFS) of patients with DLBCL

| Variable                              | 5-year OS rate (%) | P value | 5-year PFS rate (%) | P value |
|---------------------------------------|--------------------|---------|---------------------|---------|
| Age (years)                           |                    |         |                     |         |
| ≤ 60                                  | 66.7               | < 0.01  | 54.7                | 0.02    |
| > 60                                  | 42.1               |         | 38.8                |         |
| Clinical stage                        |                    |         |                     |         |
| I–II                                  | 68.2               | < 0.01  | 61.7                | < 0.01  |
| III–IV                                | 50.7               |         | 38.4                |         |
| B symptoms                            |                    | 0.02    |                     | < 0.01  |
| No                                    | 63.8               |         | 54.2                |         |
| Yes                                   | 48.7               |         | 38.7                |         |
| Spleen involvement                    |                    | 0.01    |                     | < 0.01  |
| No                                    | 62.4               |         | 53.0                |         |
| Yes                                   | 41.8               |         | 31.4                |         |
| IPI                                    |                    | < 0.01  |                     | < 0.01  |
| < 3                                   | 64.4               |         | 55.6                |         |
| ≥ 3                                   | 41.9               | < 0.01  | 29.6                | < 0.01  |
| LDH (U/L)                             |                    | < 0.01  |                     | < 0.01  |
| ≤ 245                                 | 72.7               |         | 60.1                |         |
| > 245                                 | 46.2               | < 0.01  | 39.0                |         |
| β2-MG (mg/L)                          |                    | < 0.01  |                     | 0.07    |
| ≤ 2.52                                | 73.2               |         | 54.6                |         |
| > 2.52                                | 42.2               | < 0.01  | 35.7                |         |
| Rituximab                              |                    | 0.04    |                     | 0.20    |
| Without                               | 53.1               |         | 46.4                |         |
| With                                  | 71.9               |         | 58.4                |         |
| First-line chemotherapy CR            |                    | < 0.01  |                     | 0.04    |
| No                                    | 49.1               |         | 45.9                |         |
| Yes                                   | 72.2               |         | 57.2                |         |
| PD-L1 expression in tumor cells       |                    | 0.02    |                     | 0.01    |
| Negative                              | 67.3               |         | 59.6                |         |
| Positive                              | 50.0               |         | 39.6                |         |
| PD-L1 expression in tumor microenvironment |         | 0.21    |                     | 0.26    |
| Negative                              | 62.0               |         | 52.5                |         |
| Positive                              | 48.9               |         | 39.3                |         |

*IP*: international prognostic index, *LDH*: lactate dehydrogenase, *β2-MG*: β2-microglobulin, *CR*: complete remission, *PD-L1*: programmed cell death-ligand 1
In the present study on 204 DLBCL patients, PD-L1 expression in tumor cells was an independent risk factor for OS (HR 1.40; 95% CI 1.61–10.23; \( P < 0.01 \)), but not for PFS (HR 0.46; 95% CI 1.00–2.51; \( P = 0.05 \)), in multivariate analysis. These results were in accordance with the findings by Kiyasu et al. \[5\]. Interestingly, using higher expression levels as cutoff threshold, such as over 30% of lymphoma cells expressing both PD-L1 and PAX5 used by Kiyasu et al. \[5\] and Xing et al. \[44\], is more accurate in prognostic prediction than other cutoff values in their studies. In the present study, the differences in survivals could also be distinguished using a cutoff threshold of 5%. Xing et al. \[44\] retrospectively analyzed data of 84 EBV-negative DLBCL patients and found that patients with PD-L1 expression in tumor cells had a higher proportion of non-GCB-subtype disease than those without PD-L1 expression (71% vs. 30%, \( P = 0.0060 \)). In the present study, PD-L1 expression in tumor cells and in microenvironment were associated with the non-GCB subtype (\( P = 0.02 \) and 0.04), which typically indicated a poor overall prognosis. The mechanisms responsible for the relationship between PD-L1 expression and poor prognosis are still not clear. In classical Hodgkin’s lymphoma, 9p24.1 amplification \[45\] and EBV infection \[41\] are thought to be related to the overexpression of PD-L1. Another study suggested that genetic alterations affecting the PD-L1/PD-L2 locus might lead to the overexpression of PD-L1 \[46\]. Several studies reported that ABC-subtype DLBCL prominently expressed both PD-L1 and PD-L2 \[36, 47, 48\]. Genes/pathways expressed in non-GCB subtype DLBCL showed similarity to those in ABC-subtype DLBCL \[49\], and the activation of Janus kinase (JAK)/signal transduction and activation of transcription factor 3 (STAT3) signaling might favor the constitutive expression of PD-L1 \[50\]. This phenomenon suggests that immunotherapies blocking PD-1 and PD-L1 or targeting the JAK/STAT3 signaling pathway may benefit patients with this aggressive subtype of disease.

PD-L1 positivity in tumor microenvironment was found to be associated with resistance to first-line chemotherapy in the present study. The composition and function of tumor microenvironment is an important factor for both immune escape of tumors and antitumoral defense \[51\]. PD-L1 is known to interact with CD80. CD80 expressed on activated T cells [and possibly antigen-presenting cells (APCs)] can function as a receptor rather than a ligand, delivering inhibitory signals when engaged by PD-L1 \[52\]. Understanding such complex receptor-ligand interactions in tumor microenvironment will be required to reveal potential immune checkpoint resistance mechanisms \[53\]. It is possible that small T-cell clones are more important than large T-cell clones in tumor response once effective chemotherapy regimens have significantly debulked the initial tumor load in DLBCL patients \[54\]. In DLBCL, IHC analysis of tissue biopsies has revealed an association between T-cell infiltration and response to chemotherapy \[53\]. High CD4\(^+\) T-cell infiltration has been associated with long OS in DLBCL patients treated with both anthracycline-based regimens and R-CHOP chemoimmunotherapy \[55, 56\]. Curiel et al. \[57\] reported that tumor-infiltrating PD-L1-positive myeloid dendritic cells (MDCs) suppressed the induction of interferon-gamma (IFN-\(\gamma\)) in T cells and reduced IFN-\(\gamma\)-positive T cells, indicating that PD-L1-positive MDCs induce T-cell immune suppression in tumor microenvironment. Therefore, the number of PD-L1-positive tumor-infiltrating lymphocytes (TILs) was lower in DLBCL patients with PD-L1 expression tumor microenvironment, which may be due to the suppression of T-cell induction by PD-L1-positive MDCs.

### Table 3 Multivariate analysis of prognostic factors for OS and PFS of patients with DLBCL

| Variate                                      | OS             | PFS          |
|----------------------------------------------|----------------|--------------|
|                                              | HR 95% CI P    | HR 95% CI P  |
| Age                                          | 1.38 1.69–9.40 | < 0.01       |
| Clinical stage                                | − 0.39 0.22–2.06 | 0.57       |
| B symptoms                                   | − 0.93 0.12–1.35 | 0.63       |
| Spleen involvement                           | − 0.05 0.24–3.87 | 0.95       |
| IPI                                          | 1.01 0.59–12.70 | 0.20       |
| LDH                                          | 0.29 0.49–3.67 | 0.57       |
| β2-MG                                        | 0.02 0.33–3.18 | 0.98       |
| Rituximab                                    | − 0.13 0.34–2.26 | 0.80       |
| CR after first-line chemotherapy             | − 1.54 0.09–0.49 | < 0.01     |
| PD-L1 expression in tumor cells              | 1.40 1.61–10.23 | < 0.01     |

IPI: international prognostic index, LDH: lactate dehydrogenase, β2-MG: β2-microglobulin, CR: complete remission, PD-L1: programmed cell death ligand 1, –: not included
tumor microenvironment. High number of PD-L1-positive cells in tumor microenvironment could shield the tumor against attacking TILs [51]. These may be the possible mechanisms underlying why and how PD-L1 positivity in tumor microenvironment impact the treatment resistance.

In the present study, we found that PD-L1 expression in tumor microenvironment had a negative correlation with that of C-Myc (r = −0.20, P = 0.04). C-Myc is a known oncogene in DLBCL. C-Myc gene translocation is a hallmark of Burkitt lymphoma and was detected in 5%–17% of DLBCL patients [58]. C-Myc aberrations include gene translocation, gene amplification, and mRNA or protein overexpression. Duranpanteix et al. [59] investigated the role of C-Myc in the regulation of PD-L1 expression in the P493-6 B cell line. They found that the inhibition of C-Myc expression by tetracycline led to an increase in PD-L1 mRNA expression. The regulatory region of PD-L1 gene does not contain a binding site for C-Myc, whereas STAT1 and interferon regulatory factor 1 (IRFI) directly bind to the promoter of PD-L1 gene to increase its transcription, suggesting that C-Myc would repress PD-L1 expression at the mRNA level via STAT1 inhibition [59].

The mechanism of the relationship between C-Myc and PD-L1 expression in tumor environment in the present study needs to be further explored. Casey et al. [60] have shown that C-Myc regulated the antitumor immune response through binding the promoter region and activating the transcription of CD47 and PD-L1, and C-Myc appeared to initiate and maintain tumorigenesis in a mouse model of Myc-induced T-cell acute lymphoblastic leukemia. Inactivation of Myc could result in the down-regulation of PD-L1, thus restoring recruitment of T cells and macrophages and causing tumor shrinkage. Besides, Rossille et al. [61] showed that patients with high levels of serum PD-L1 had a significantly shorter OS than those with low levels of serum PD-L1 within the BCL2-positive population. Therefore, in Myc-driven malignancies or even high-grade B-cell lymphomas, especially in those with Myc rearrangement, such as double-hit or triple-hit lymphomas, Myc- and PD-L1-targeted combination therapy may be of potential therapeutic benefit.

Several limitations should be noted when interpreting the results of the present work. As a retrospective study, the long time span for the storage of paraffin-embedded samples may affect the results of PD-L1 detection. The missing clinical data may also affect the accuracy of statistical analysis. Therefore, a study with a larger population is needed to verify our findings. It remains unclear whether the expression of PD-L1 is a key factor associated with the clinical prognosis of DLBCL patients treated with PD-1/PD-L1 blockade therapy. Further integration of genomic and clinical data is expected to deepen our understanding of PD-L1 in DLBCL.

Conclusions
In conclusion, the expression of PD-L1 in both tumor cells and microenvironment is associated with the non-GCB-subtype DLBCL. PD-L1 expression in tumor microenvironment has a negative correlation with the expression of C-Myc, which indicates a role of C-Myc in the regulation of PD-L1 expression. PD-L1 predicts short survival in DLBCL patients. For patients with PD-L1 expression in tumor cells, more strategy such as anti-PD-L1 antibody treatment should be recommended.
References

1. Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 2006;108(1):19–24.

2. Zou W, Wolchok JD, Chen L, PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv324.

3. Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: a novel role of programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007;13(7):2151–7.

4. Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood. 2015;126(19):2193–201.

5. Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Tox‑inhibition of programmed death‑1 pathway by nivolumab in patients with advanced squamous‑cell non‑small‑cell lung cancer. N Engl J Med. 2015;373(2):123–35.

6. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.

7. Villasoa JC, Ansell SM. Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab. Expert Rev Anticancer Ther. 2016;16(1):1–5.

8. Bryan LJ, Gordon LI. Pitiluzumab in the treatment of diffuse large B-cell lymphoma. Expert Opin Biol Ther. 2014;14(9):1361–8.

9. Cai Q-Q, Hu L-Y, Geng Q-R, Chen J, Lu Z-H, Rao H-L, et al. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study. Chin J Cancer. 2016;35(1):187.

10. He X-H, Li B, Yang S, Lu N, Zhang X, Zou S-M, et al. PD-1/PD-L1 inhibitors in lymphoma: case report and review of literature. Int J Clin Exp Med. 2015;8(5):6977.

11. Chuang WY, Chang H, Shih LY, Wang PN, Chang YS, Lin TL, et al. CD8 positive is an independent adverse prognostic factor in elderly patients with diffuse large B-cell lymphoma. Virchows Arch. 2015;465(7):571–82.

12. Hao X, Wei X, Huang F, Wei Y, Zeng H, Xu L, et al. The expression of CD30 on lymphoma tissue is an independent adverse prognostic factor in elderly patients. Int J Hyperthermia. 2015;31(2):136–44.

13. Boger C, Behrens HM, Mathiak M, Kruger S, Kalthoff H, Rocken C. PD-L1 positivity is an independent adverse prognostic factor in gastric cancer patients with diffuse large B-cell lymphoma. Virchows Arch. 2015;465(7):571–82.

14. Hoeller S, Tzankov A, Pileri SA, Went P, Dirnhofer S. Epstein–Barr virus‑positive diffuse large B-cell lymphoma after failure of autologous stem cell transplant and brentuximab. Expert Opin Biol Ther. 2016;16(1):1–5.

15. Brahmer J, Reckamp KL, Baas P, Crin L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430.

16. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.

17. Villasoa JC, Ansell SM. Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab. Expert Rev Anticancer Ther. 2016;16(1):1–5.

18. Bryan LJ, Gordon LI. Pitiluzumab in the treatment of diffuse large B-cell lymphoma. Expert Opin Biol Ther. 2014;14(9):1361–8.

19. Cai Q-Q, Hu L-Y, Geng Q-R, Chen J, Lu Z-H, Rao H-L, et al. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study. Chin J Cancer. 2016;35(1):187.

20. He X-H, Li B, Yang S, Lu N, Zhang X, Zou S-M, et al. PD-1/PD-L1 inhibitors in lymphoma: case report and review of literature. Int J Clin Exp Med. 2015;8(5):6977.

21. Chuang WY, Chang H, Shih LY, Wang PN, Chang YS, Lin TL, et al. CD8 positive is an independent adverse prognostic factor in elderly patients with diffuse large B-cell lymphoma. Virchows Arch. 2015;465(7):571–82.
45. Menter T, Bodmer-Haecki A, Dimhofer S, Tzankov A. Evaluation of the diagnostic and prognostic value of PD-L1 expression in Hodgkin and B-cell lymphomas. Hum Pathol. 2016;54:17–24.

46. Georgiou K, Chen L, Berghlund M, Ren W, de Miranda NF. Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. Blood. 2016;127(24):3026–34. https://doi.org/10.1182/blood-2015-12-686550 (Epub 2016 Mar 30).

47. Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17(13):4232–44. https://doi.org/10.1158/1078-0432.ccr-10-2660 (Epub 2011 May 3).

48. Berghoff AS, Ricken G, Widhalm G, Rajkó O, Hainfellner JA, Birner P, et al. PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (pcnsL). Clin Neuropathol. 2014;33(1):42–9.

49. Bsc JG, Hooijkaas AJ, Kaiser ADM, Tinteren HV, van Boven H, Blank C. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer. 2011;117(10):2192–201.

50. Green MR, Monti S, Rodrig SJ, Jaszczynski P, Currie T, O'Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268–77.

51. Mitteldorf C, Berisha A, Pfaltz MC, Smc B, Schön MP, Kerl K, et al. Tumor microenvironment and checkpoint molecules in primary cutaneous diffuse large B-cell lymphoma-new therapeutic targets. Am J Surg Pathol. 2017;41(7):998.

52. Butte M, Keir M, Phamduy T, Sharpe A, Freeman G. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111.

53. Nicholas NS, Apollonio B, Ramsay AG. Tumor microenvironment (TME)-driven immune suppression in B cell malignancy: BBA Mol Cell Res. 2016;1863(3):471.

54. Keane C, Gould C, Jones K, Hamm D, Talaulikar D, Ellis J, et al. The T-cell receptor repertoire influences the tumor microenvironment and is associated with survival in aggressive B-cell lymphoma. Clin Cancer Res. 2017;23(7):1820.

55. Keane C, Gill D, Vari F, Cross D, Griffiths L, Gandhi M. CD4+ tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy. Am J Hematol. 2013;88(4):273–6.

56. Ansell SM, Stenson M, Habermann TM, Jelinek DF, Witzig TE. CD4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol. 2001;19(3):720.

57. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9(5):562–7.

58. Slack GW, Gascoyne RD. Myc and aggressive B-cell lymphomas. Adv Anat Pathol. 2011;18(3):219.

59. Durandpanteix S, Farhat M, Youlyouzmarfak I, Rouaud P, Oukmartin C, Slack GW, et al. B7-H1, which represses EBV-immortalized B cell killing by autologous T and NK cells, is oppositely regulated by c-Myc and EBC latency III program at both mRNA and secretory lysosome levels. J Immunol. 2012;189(1):181.

60. Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, et al. Myc regulates the anti-tumor immune response through CD47 and PD-L1. Science. 2016;352(6282):227.

61. Bossile D, Gressier M, Damotte D, Mauco-d-Boulch D, Pagnaut C, Semana G, et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial. Leukemia. 2014;28(12):2367–75.